Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

Precision Chemotherapy Based on Organoid for Colorectal CancerPatient-Derived Tumor Organoid Drug Sensitivity for Colorectal Cancer: A Prospective, Multicentre，Randomized, Controlled Trial

The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.

Fluorouracil-based chemotherapy is the standard treatment for stage IV colorectal cancer patients. However, the effects of chemotherapy remains limited. Patient-derived tumor organoids are increasingly used as tools for drug test and predicting drug response in the clinic, and have been showed to faithfully predict clinical outcomes of patients with CRC. A prospective clinical trial is needed to validate whether the in vitro sensitivity to chemotherapy regimens in organoids drug test is associated with a longer PFS in stage IV colorectal cancer.

Inclusion Criteria:

• Age between 18 and 70
• Histological confirmed colorectal cancer
• Stage IV
• American Society of Anesthesiologists (ASA) score I~III
• No contraindication for chemotherapy
• No evidence of other malignant tumor

Exclusion Criteria:

• Refusing chemotherapy
• Pregnant or breast-feeding women
• Severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy